ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Dr. Carvajal Describes MEK Inhibition in Uveal Melanoma

Richard D. Carvajal, MD
Published: Saturday, Jun 01, 2013



Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition using the agent selumetinib in patients with advanced uveal melanoma.

The trial exploring selumetinib was the first to discover an effective agent for patients with advanced uveal melanoma. Even though the MEK inhibitor trametinib was recently approved, Carvajal believes clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.

<<< View more from the 2013 ASCO Annual Meeting



Richard D. Carvajal, MD, a medical oncologist at Memorial Sloan-Kettering Cancer Center, describes the success of MEK inhibition using the agent selumetinib in patients with advanced uveal melanoma.

The trial exploring selumetinib was the first to discover an effective agent for patients with advanced uveal melanoma. Even though the MEK inhibitor trametinib was recently approved, Carvajal believes clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.

<<< View more from the 2013 ASCO Annual Meeting


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Advances in™ Melanoma: Exploring BRAF/MEK in Adjuvant and Neoadjuvant SettingsSep 28, 20191.5
Publication Bottom Border
Border Publication
x